HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $27
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen maintains a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and raises the price target from $25 to $27.
May 19, 2023 | 10:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on EyePoint Pharmaceuticals and raises the price target from $25 to $27.
The news of HC Wainwright & Co. maintaining a Buy rating on EyePoint Pharmaceuticals and raising the price target from $25 to $27 is positive for the company. This indicates that the analyst has confidence in the company's growth potential and expects the stock price to rise in the short term. As a result, the short-term impact on EYPT's stock price is likely to be positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100